Clinical trial · Interventional
Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging
Radioimmunodetection of CEA-Producing Tumors Using a Bispecific Antibody Pre-targeting Method and an In-Labeled Peptide
NCT00185081CI-TRIAL-00021673completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test the safety of the peptide and antibody and at the same time evaluate the tumor imaging of a two step antibody technique in nuclear imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colonic Neoplasms | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Indium labeled IMP-205xm734 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Safety evaluation of intravenous injection of In-labeled IMP-205 and hMN-14xm734
- measure
- Tumor targeting of In-IMP-205 in patients with colorectal carcinoma
- measure
- Pharmacokinetics, biodistribution and dosimetry of In-IMP-205
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 years of age * Histologic or cytologic diagnosis of colorectal cancer * Karnofsky performance status \>70% Exclusion Criteria: * Pregnant or lactating women * Severe anorexia * Active second primary malignancy * Chemotherapy or radiotherapy within four weeks of study entry
References
Publications (0)
Data not yet available
No reference posted for this study.